Table 167GRADE evidence profile: Methotrexate, Paclitaxel, Epirubicin, Carboplatin for second-line chemotherapy

Quality assessmentNo of patientsEffectQuality
No of studiesDesignRisk of biasInconsistencyIndirectnessImprecisionOther considerationsMPECControlRelative
(95% CI)		Absolute
Overall survival (median (range) follow-up: 14 (3-45) months)
11observational studiesnonenonenoneserious2noneMedian OS 12.5 months---⊕○○○
VERY LOW
Progression-free survival (median (range) follow-up: 14 (3-45) months)
11observational studiesnonenonenoneserious2noneMedian PFS 12 months---⊕○○○
VERY LOW
Overall tumour response rate (assessed with: WHO criteria)
11observational studiesnonenonenoneserious2none15/38
(39.5%)		---⊕○○○
VERY LOW
Grade 3-4 Neutropenia (assessed with: NCI-CTC)
11observational studiesnonenonenoneserious2none12/40
(30%)		---⊕○○○
VERY LOW
Grade 3-4 Thrombocytopenia (assessed with: NCI-CTC)
11observational studiesnonenonenoneserious2none1/40
(2.5%)		---⊕○○○
VERY LOW
Grade 3-4 Anaemia (assessed with: NCI-CTC)
11observational studiesnonenonenoneserious2none2/40
(5%)		---⊕○○○
VERY LOW
Treatment-related mortality
0No evidence available
Health-related quality of life
0No evidence available
1
2

Low number of events/small sample size limits precision

From: 5, Managing locally advanced or metastatic bladder cancer

Cover of Bladder Cancer
Bladder Cancer: Diagnosis and Management.
NICE Guideline, No. 2.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.